# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Kelly Shi initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price T...
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform ra...
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.
Foghorn Therapeutics Inc. ("Foghorn") (NASDAQ:FHTX) today announced the pricing of a registered direct offering of 12,7...